Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis

Author:

Javed Faiza1,Kumar Anoop12

Affiliation:

1. Department of Clinical Research, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India

2. Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India

Abstract

Background: Early signal detection from post-marketing studies play a vital role in the safety of patients. Recent case reports have indicated the association of clindamycin with renal failure acute. However, renal failure acute is not known to be associated with clindamycin. The aim of the study was the identification of the potential signal of clindamycin-associated renal failure acute. Methods: The OpenVigil 2.1-MedDRA-v24 was used to query the FAERS database. The Reporting Odds Ratio (ROR) with a 95% confidence interval, was used to assess the association between clindamycin and renal failure acute. Results: A total of 22326 cases associated with renal failure acute were found in OpenVigil 2.1- MedDRA-v24. Among these 125 were associated with clindamycin. The ROR was found to be 3.2 (2.7, 3.8) which indicates a statistically significant association between clindamycin and renal failure acute reporting. The signal strength was decreased after removing the cases of concomitantly administered drugs, however, the association of clindamycin with renal failure acute reporting remains statistically significant. The subgroup analysis results have also shown a positive signal of clindamycin with renal failure acute. Conclusions: The current study identified a positive signal of clindamycin as renal failure acute. However, further validation and causality assessment are required.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Pharmacology,Toxicology

Reference21 articles.

1. World health organization. Quality Assurance and Safety of Medicines Team. Safety of Medicines. Aguide to delicting and report adverse durg reaction, Wht health professionals need to take action. WHO 2002

2. Subeesh V.; Singh H.; Maheswari E.; Beulah E.; Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. Asian J Psychiatr 2017,30,152-156

3. Sharma A.; Kumar A.; Identification of novel signal of clobazam‐associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis. Acta Neurol Scand 2022,146(5),623-627

4. Spížek J.; Řezanka T.; Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol 2004,64(4),455-464

5. Summary of product characteristics (SmPC) of clindamycin. Electronic Medicines Compendium. Available from: [Accessed on: 30th Sep 2021].

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3